Thielmann, C. M., Matull, J., Zaremba, A., Murali, R., Chorti, E., Lodde, G., Jansen, P., Herbst, R., Terheyden, P., Utikal, J., Pföhler, C., Ulrich, J., Kreuter, A., Mohr, P., Gutzmer, R., Meier, F., Dippel, E., Weichenthal, M., Kretz, J., Möller, I., Sucker, A., Paschen, A., Livingstone, E., Zimmer, L., Hadaschik, E., Ugurel, S., Schadendorf, D., & Griewank, K. G. (2022). tERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European journal of cancer, 161, 99–107. http://access.bl.uk/ark:/81055/vdc_100148174693.0x000016